STOCK TITAN
  1. Home
  2. Sec-filings
  3. VNRX
  4. [8-K] VOLITIONRX LTD Reports Material Event

VolitionRx Limited (NYSE: VNRX) doubles H1 2026 revenue and trims losses

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

VolitionRx Limited reported first half 2026 revenue of $1.4 million, an increase of 112% over the first half of 2025. Second quarter 2026 revenue was approximately $0.4 million, broadly consistent with the prior-year quarter. Management highlighted progress across its Nu.Q® Vet, Nu.Q® Lung Cancer and Capture-Seq™ liquid biopsy platforms, and active licensing discussions with more than a dozen major diagnostic and liquid biopsy companies.

Operating expenses in the second quarter of 2026 were 32% lower than a year earlier, contributing to a reduced operating loss of $4.2 million, down 34% versus the comparable 2025 quarter. Net cash used in operating activities was $5.2 million, 18% lower year-on-year. Second quarter receipts included $1.2 million from at-the-market equity sales and $4.1 million from a confidentially marketed public offering of shares and warrants.

The company cited a total addressable market of more than $27 billion across its product pillars and noted a collaboration with Sysmex Corporation, a submitted Nu.Q® Vet feline lymphoma manuscript linked to a potential $5 million milestone, and ongoing reimbursement work for Nu.Q® Lung Cancer in Europe.

Positive

  • First half 2026 revenue rose 112% to $1.4 million versus the first half of 2025, while second quarter operating expenses fell 32% and operating loss declined 34%, indicating meaningful early revenue growth alongside tighter cost control.
  • Net cash used in operating activities in the second quarter of 2026 fell 18% to $5.2 million, showing reduced cash burn as the company advances collaborations, licensing discussions and prepares for potential reimbursement of Nu.Q® Lung Cancer.

Negative

  • The company remains loss-making with a second quarter 2026 operating loss of $4.2 million and net cash used in operating activities of $5.2 million, funded in part by $5.3 million of equity issuance proceeds.
First half 2026 revenue $1.4 million 112% growth over the first half of 2025
Q2 2026 revenue approximately $0.4 million In line with the same period in 2025
Q2 2026 operating loss $4.2 million Down 34% versus the comparable quarter in 2025
Q2 2026 net cash used in operating activities $5.2 million 18% lower than the same quarter in 2025
ATM equity proceeds in Q2 2026 $1.2 million Net proceeds from equity sales through at-the-market facility
Confidentially marketed public offering proceeds $4.1 million Net proceeds from issuance of shares and warrants in Q2 2026
Total Addressable Markets more than $27 billion Annualized TAM across all product pillars
Potential Nu.Q Vet feline milestone $5 million Contractual milestone tied to publication of feline lymphoma study
at-the-market facility financial
"included $1.2 million in net proceeds from equity sales through our at-the-market facility"
An at-the-market facility is a standing arrangement that lets a publicly traded company sell new shares directly into the open market at whatever the current market price is, typically through an investment bank acting as a sales agent. For investors it matters because it provides the company with a flexible way to raise cash without a large, one-time share offering; however, selling additional shares can dilute existing ownership and, by increasing supply, may pressure the stock price like adding more tickets to a limited-seat event.
confidentially marketed public offering financial
"$4.1 million in net proceeds from the issuance of shares and warrants in a confidentially marketed public offering"
A confidentially marketed public offering is a planned sale of a company's shares to the public that is promoted privately to a small group of investors before being announced broadly. Think of it like quietly asking a few trusted buyers if they’re interested before putting items up for sale in a public marketplace; it lets the company test demand, set price expectations and limit market disruption. For investors, it signals potential share dilution, gives clues about demand and pricing, and may affect short-term stock volatility and investment decisions.
Total Addressable Markets financial
"The Total Addressable Markets1 (TAMs) for our technologies, on an annualized basis, are multi-billion-dollar opportunities"
An estimate of the total revenue opportunity available for a product or service if every potential customer in a defined market were to buy it, essentially the full size of the market 'pie.' Investors use it to judge how big a business could grow and to compare opportunities across companies; think of it as the pizza’s total size, not the slice a company is likely to actually capture.
Neutrophil Extracellular Traps medical
"where Neutrophil Extracellular Traps ("NETS") play such an important role"
Neutrophil extracellular traps (NETs) are web-like strands of DNA and proteins expelled by certain white blood cells to trap and neutralize invading germs, like a spider spinning a sticky web to catch insects. For investors, NETs matter because they are linked to inflammation, blood clots and chronic disease, making them potential targets for new diagnostics and therapies and a factor in safety and efficacy assessments for drug and device development.
NETosis medical
"diseases associated with NETosis, such as sepsis"
Netosis is a process where a type of white blood cell ejects a sticky web-like mesh to trap germs, sacrificing itself in the process. While intended as a protective response, these nets can also spark inflammation, blood clots or tissue damage, so they matter to investors because drugs that alter netosis can become new therapies or safety risks, affect clinical trial outcomes, and influence regulatory and market value for companies working on related diagnostics or treatments.
reimbursement submission regulatory
"working with our long-term collaborators ... on the reimbursement submission for Nu.Q Lung Cancer"
First half 2026 revenue $1.4 million 112% growth over the first half of 2025
Q2 2026 revenue approximately $0.4 million in line with the same period in 2025
Q2 2026 operating loss $4.2 million down 34% versus the comparable quarter in 2025
Q2 2026 net cash used in operating activities $5.2 million 18% lower than the same quarter in 2025

FAQ

How did VolitionRx (VNRX) perform financially in the first half of 2026?
VolitionRx reported first half 2026 revenue of $1.4 million, a 112% increase over the first half of 2025. Second quarter 2026 revenue was about $0.4 million, broadly in line with the same quarter of 2025.

What were VolitionRx (VNRX)’s losses and cash burn in Q2 2026?
VolitionRx recorded an operating loss of $4.2 million in the second quarter of 2026. Net cash used in operating activities was $5.2 million, representing an 18% reduction compared with the same quarter in 2025.

How did VolitionRx (VNRX) fund its operations in the second quarter of 2026?
Second quarter 2026 receipts included $1.2 million in net proceeds from equity sales through an at-the-market facility and $4.1 million from a confidentially marketed public offering of shares and warrants, supporting ongoing operations.

What is the revenue potential of VolitionRx (VNRX)’s product portfolio?
VolitionRx estimates its annualized Total Addressable Markets exceed $27 billion across all product pillars. This multi-billion-dollar opportunity is positioned for both the company and potential licensing partners using its epigenetic testing technologies.

What upcoming milestones did VolitionRx (VNRX) highlight for 2026?
The company noted a submitted Nu.Q® Vet feline lymphoma manuscript linked to a potential $5 million milestone, collaboration with Sysmex Corporation, and work on reimbursement for Nu.Q® Lung Cancer as it advances toward routine clinical use.

When is VolitionRx (VNRX)’s second quarter 2026 earnings conference call?
The second quarter 2026 earnings and business update call is scheduled for Friday, August 14, 2026 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. Central European Time), with webcast and replay options available.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

  EXHIBIT 99.1

 

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

 

Conference call to discuss financial and operational results scheduled for

 

Friday, August 14 at 8:30 a.m. U.S. Eastern Time

 

Henderson, Nevada, August 13, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results and a business update for the second quarter of 2026. Volition management will host a conference call tomorrow, August 14 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.

 

Cameron Reynolds, President and Group Chief Executive Officer, said:

 

“We have made strong progress across all of our product pillars throughout 2026 to date.

 

“We are currently in discussions, including undertaking technology evaluations, with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue. Discussions are at various stages of the negotiation process across our different pillars with our laser focus on executing further licensing agreements.

 

“We announced our collaboration with Sysmex Corporation, a global leader in the field of in vitro diagnostics for hemostasis and thrombosis, among other diseases, where Neutrophil Extracellular Traps ("NETS") play such an important role.

 

“In May, we announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q® Vet platform.

 

“We are working with our long-term collaborators at the Hospices Civils de Lyon, one of Europe's leading cancer centers, on the reimbursement submission for Nu.Q® Lung Cancer. Reimbursement is the last step on the path to the first use of Nu.Q® in routine clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives.

 

“We continue to add to our significant data rooms with published, submitted and confidential data across our product pillars. Most notably, we recently announced the publication of our first peer-reviewed paper demonstrating our breakthrough Capture-Seq™ liquid biopsy technology.

 

“The Total Addressable Markets1 (TAMs) for our technologies, on an annualized basis, are multi-billion-dollar opportunities (estimated at more than $27 billion across all of our product pillars), not only for Volition, but for our licensing partners. Volition has made strong progress, both clinically and commercially, and our technology is now poised to be used very widely in a broad range of clinical utilities.”

 

 
1

 

 

Financial Highlights

 

·

First half of 2026 revenue was $1.4 million, 112% growth over the first half of 2025

·

Revenue for the second quarter of 2026 was approximately $0.4 million, in line with the same period in 2025

·

Operating expenses for the second quarter of 2026 were 32% lower than the same quarter in 2025, reflecting the impact of our cost reduction program

·

Operating loss was $4.2 million for the second quarter of 2026, down 34% versus the comparable quarter in 2025

·

Net cash used in operating activities was $5.2 million for the second quarter of 2026, 18% lower than the same quarter in 2025

·

Receipts in the second quarter of 2026 included:

 

○

$1.2 million in net proceeds from equity sales through our at-the-market facility

 

○

$4.1 million in net proceeds from the issuance of shares and warrants in a confidentially marketed public offering

 

Event: VolitionRx Limited Second Quarter 2026 Earnings and Business Update Conference Call

 

Date: Friday, August 14, 2026

Time: 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time

 

U.S. & Canada Dial-in: 1-877-407-9716 (toll free)

U.K. Dial-in: 0 800 756 3429 (toll free)

Toll/International: 1-201-493-6779

Conference ID: 13762190

 

Louise Batchelor, Group Chief Marketing & Communications Officer of Volition will host the call along with Cameron Reynolds, President and Group Chief Executive Officer and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the second quarter of 2026, subsequent events and upcoming milestones.

 

A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until August 28, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13762190.

 

1. Data on File, VNRX TAM Model

 

About Volition

 

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

 

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

 

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

 

The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

 

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

 

 
2

 

 

Safe Harbor Statement

 

Statements contained or referenced herein, including in any associated video or link, may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are those that are not statements of historical fact and instead address predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify such statements.

 

These forward-looking statements relate to, among other topics, Volition's expectations regarding revenue opportunities and growth; the effectiveness and availability of its blood-based diagnostic, prognostic and disease monitoring tests; its ability to develop and successfully commercialize such test platforms for the early detection and monitoring of cancer and other diseases; its expectations regarding future publications; and its success in securing, and the terms of, licensing and/or distribution or other agreements with third parties.

 

Forward-looking statements are based on current expectations, estimates and projections about Volition's business, in part on assumptions made by management. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those anticipated. These risks and uncertainties include, without limitation: the results of studies testing the efficacy of Volition's tests; failure to develop and commercialize its products, which may prevent it from executing its plan of operations; failure to obtain necessary regulatory clearances or approvals; failure to achieve healthcare system or insurance reimbursement; failure of the marketplace to accept its products; failure to secure adequate intellectual property protection; the highly competitive and rapidly evolving nature of the diagnostics and disease monitoring market, which may render its products obsolete; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission.

 

Forward-looking statements are made as of the date hereof and, except as required by law, Volition undertakes no obligation to update them to reflect future events or circumstances.

 

Nu.Q®, Nucleosomics™, Capture-PCR™, Capture-Seq™ and rNuQ™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to “$” refer to the legal currency of the United States of America.

 

 
3

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

6 documents

Press Releases

Other Documents